Midatech, Immunotope create immunotherapy JV

A British company specializing in nanotech drug delivery and a U.S. biotech company are reaching across the Atlantic to form a joint venture.

Midatech Group, based in the UK, designs and synthesizes 5-nanometer particles that can target specific cells for drug delivery. Immunotope, based in Doylestown, PA, develops immunotherapy products to treat cancer and chronic viral infections. Together, the two companies have given birth to Syntara, which will develop antigen based products for immune therapies to treat chronic viral infections and certain cancers.

The new company will be based in the United States. Both Immunotope and Midatech will license IP to Syntara. The companies said in a news release that the joint venture combines Midatech's expertise in nanomedicine with Immunotope's experience in immunotherapeutic antigen discovery and validation.

"The joint venture provides a route to nurture the development of new products for the treatment of certain cancers and chronic infections," said Professor Tom Rademacher, chairman of Midatech.

.- see the press release
- read the story in the Philadelphia Business Journal


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.